Importance The treatment landscape for advanced hepatocellular carcinoma (HCC) has
recently changed and become relatively confusing. Head-to-head comparisons between …

Regorafenib is a diphenylurea oral multikinase inhibitor, structurally comparable to
sorafenib, which targets a variety of kinases implicated in angiogenic and tumor growth …

Recent years have seen significant progress in the systemic treatment of hepatocellular
carcinoma (HCC), including the advent of immunotherapy. While several large phase III …

Background & Aims Sorafenib is first-line standard of care for patients with advanced
hepatocellular carcinoma (HCC), yet it confers limited survival benefit. Therefore, we aimed …

Hepatocellular carcinoma (HCC) ranks among the most common cancers worldwide and
remains to be a major global health care problem. Until 2007, no effective therapies were …

Despite advances in biomedicine, the incidence and the mortality of hepatocellular
carcinoma (HCC) remain high. The majority of HCC cases are diagnosed in later stages …

Background: Patients with advanced hepatocellular carcinoma (HCC) typically have poor
survival outcomes. Until recently, sorafenib was the only systemic therapy option available …

Introduction: Atezolizumab (ATEZO) plus bevacizumab (BEVA) represents the new standard
of care for the treatment of advanced hepatocellular carcinoma (HCC). However, the choice …

Background Concurrent chemoradiotherapy is an established component of the
nonoperative management of locally advanced head and neck squamous cell carcinoma …

Lenvatinib, which is an oral multikinase inhibitor, showed non-inferiority to the sorafenib in
terms of overall survival (OS) and a higher objective response rate (ORR) and better …